Vertex Pharmaceuticals Inc. Stock Sheds 4.3%, Underperforms Peers
Dow Jones2026/10/13 20:34This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. slid 4.3% to $485.22 on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index remaining mostly unchanged at 7,805.45 and the Dow Jones Industrial Average falling 0.3% to 51,670.10.
This was the stock's second consecutive day of losses.
Vertex Pharmaceuticals Inc. closed 13.4% below its 52-week high of $560.25, which the company achieved on September 3rd.
The stock demonstrated a mixed performance when compared to some of its peers, as AbbVie Inc. fell 2.4% to $274.36, Krystal Biotech Inc. fell 3.3% to $321.16, and Arcturus Therapeutics Holdings Inc. fell 4.60% to $12.03.
Trading volume totaled 1.1 million, compared to the 50-day average of 1.1 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 13, 2026 16:34 ET (20:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Worst-Performing Altcoins This Week as BTC Battles to Hold $80K: Weekend Watch
Goldman Sachs dramatically lowers KOSPI target from 12,000 to 9,000 points, still insists there is 60% upside potential
Goldman Sachs strategists have lowered their 12-month target for South Korea's KOSPI Index from 12,000 points to 9,000 points, representing a 25% decrease. Earlier this year, Goldman had raised the target multiple times. The latest downgrade is due to mounting concerns in the market over artificial intelligence (AI) trading.
AI investment has not ended; wealth is simply being redistributed.
Crypto prices
More
